CD40 and glioblastoma: The outcomes of these trials are being awaited with anticipation after a mouse study reported that the CD40 agonistic antibody induced ICB and extended the median survival of GBM model mice to 37.0 days compared with 21 days in control, indicating the tremendous potential of CD40 agonists in GBM treatment (55).